Outcomes of systemic targeted therapy in recurrent renal cell carcinoma treated with adjuvant sunitinib.
Guillermo de VelascoÁlvaro Ruiz-GranadosOscar ReigFrancesco MassariMiguel Angel Climent DuranElena VerzoniJeffrey GrahamRoberto LlarenaMichele De TursiFrede DonskovClara IglesiasHardev S PandhaXavier Garcia Del MuroGiuseppe ProcopioStephane Marie OudardDaniel CastellanoLaurence AlbigesPublished in: BJU international (2021)
Rechallenge with sunitinib or other systemic therapies is still a feasible therapeutic option that provides patients with advanced or metastastic RCC with additional clinical benefits with regard to PFS and OS after failed response to adjuvant sunitinib.